Topical application of a TRPA1 antagonist reduced nociception and inflammation in a model of traumatic muscle injury in rats.
Sabrina Qader KudsiCaren Tatiane de David AntoniazziCamila CamponogaraGraziela Moro MeiraMarcella de Amorim FerreiraAna Merian da SilvaDiéssica Padilha DalenogareRubya ZaccaronCarolina Dos Santos SteinPaulo Cesar Lock SilveiraRafael Noal MorescoSara Marchesan OliveiraJuliano FerreiraGabriela TrevisanPublished in: Inflammopharmacology (2023)
Musculoskeletal pain is a widely experienced public healthcare issue, especially after traumatic muscle injury. Besides, it is a common cause of disability, but this pain remains poorly managed. However, the pathophysiology of traumatic muscle injury-associated pain and inflammation has not been fully elucidated. In this regard, the transient receptor potential ankyrin 1 (TRPA1) has been studied in inflammatory and painful conditions. Thus, this study aimed to evaluate the antinociceptive and anti-inflammatory effect of the topical application of a TRPA1 antagonist in a model of traumatic muscle injury in rats. The mechanical trauma model was developed by a single blunt trauma impact on the right gastrocnemius muscle of Wistar male rats (250-350 g). The animals were divided into four groups (Sham/Vehicle; Sham/HC-030031 0.05%; Injury/Vehicle, and Injury/HC-030031 0.05%) and topically treated with a Lanette® N cream base containing a TRPA1 antagonist (HC-030031, 0.05%; 200 mg/muscle) or vehicle (Lanette® N cream base; 200 mg/muscle), which was applied at 2, 6, 12, 24, and 46 h after muscle injury. Furthermore, we evaluated the contribution of the TRPA1 channel on nociceptive, inflammatory, and oxidative parameters. The topical application of TRPA1 antagonist reduced biomarkers of muscle injury (lactate/glucose ratio), spontaneous nociception (rat grimace scale), inflammatory (inflammatory cell infiltration, cytokine levels, myeloperoxidase, and N-acetyl-β-D-glucosaminidase activities) and oxidative (nitrite levels and dichlorofluorescein fluorescence) parameters, and mRNA Trpa1 levels in the muscle tissue. Thus, these results demonstrate that TRPA1 may be a promising anti-inflammatory and antinociceptive target in treating muscle pain after traumatic muscle injury.
Keyphrases
- skeletal muscle
- healthcare
- spinal cord injury
- oxidative stress
- anti inflammatory
- chronic pain
- neuropathic pain
- type diabetes
- pain management
- nitric oxide
- multiple sclerosis
- insulin resistance
- metabolic syndrome
- clinical trial
- mesenchymal stem cells
- bone marrow
- social media
- weight loss
- single molecule
- health insurance
- climate change
- double blind
- cerebral ischemia
- postoperative pain